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Abstract 
Pharmacovigilance (PV) plays a key role in the healthcare system through assessment, monitoring and 
discovery of interactions amongst drugs and their effects in human. Pharmaceutical and 
biotechnological medicines are designed to cure, prevent or treat diseases; however, there are also 
risks particularly adverse drug reactions (ADRs) can cause serious harm to patients. Thus, for safety 
medication ADRs monitoring required for each medicine throughout its life cycle, during development 
of drug such as pre-marketing including early stages of drug design, clinical trials, and post-marketing 
surveillance. PV is concerns with the detection, assessment, understanding and prevention of ADRs. 
Pharmacogenetics and pharmacogenomics are an indispensable part of the clinical research. Variation 
in the human genome is a cause of variable response to drugs and susceptibility to diseases are 
determined, which is important for early drug discovery to PV. Moreover, PV has traditionally 
involved in mining spontaneous reports submitted to national surveillance systems. The research 
focus is shifting toward the use of data generated from platforms outside the conventional framework 
such as electronic medical records, biomedical literature, and patient-reported data in health forums. 
The emerging trend in PV is to link premarketing data with human safety information observed in the 
post-marketing phase. The PV system team obtains valuable additional information, building up the 
scientific data contained in the original report and making it more informative. This necessitates an 
utmost requirement for effective regulations of the drug approval process and conscious pre and post 
approval vigilance of the undesired effects, especially in India. Adverse events reported by PV system 
potentially benefit to the community due  to their proximity to both population and public health 
practitioners, in terms of language and knowledge, enables easy contact with reporters by 
electronically. Hence, PV helps to the patients get well and to manage optimally or ideally, avoid 
illness is a collective responsibility of industry, drug regulators, clinicians and other healthcare 
professionals to enhance their contribution to public health. This review summarized objectives and 
methodologies used in PV with critical overview of existing PV in India, challenges to overcome and 
future prospects with respect to Indian context. 
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Pharmacovigilance (PV) was officially introduced in December 1961 with the publication of a 
letter (case report) in the Lancet by W. McBride, the Australian doctor who first suspected a 
causal link between serious fetal deformities (phocomelia) and thalidomide, a drug used during 
pregnancy: Thalidomide was used as an antiemetic and sedative agent in pregnant women [1]. In 
1968, the World Health Organization (WHO) promoted the “Programme for International Drug 
Monitoring”, a pilot project aimed to centralize world data on adverse drug reactions (ADRs). In 
particular, the main aim of the “WHO Programme” was to identify the earliest possible PV 
signals. The term PV was proposed in the mid-70s by a French group of pharmacologists and 
toxicologists to define the activities promoting “The assessment of the risks of side effects 
potentially associated with drug treatment” [2]. 
PV is the science of collecting, monitoring, researching, assessing and evaluating information 
from healthcare providers and patients on the adverse effects of medications, biological products, 
blood products, herbals, vaccines, medical device, traditional and complementary medicines with 
a view to identifying new information about hazards associated with products and preventing 
harm to patients. The challenge of maximizing drug safety and maintaining public confidence 
has become increasingly complex. Pharmaceutical and biotechnology companies must not only 
monitor, but also proactively estimate and manage drug risk throughout a product’s lifecycle, 
from development to post-market [3]. 
PV is particularly concerned with ADRs, which are drug responses that are noxious and 
unintended, and which occur at doses normally used for the prophylaxis, diagnosis or therapy of 
disease, or for the modification of physiological function [4]. Continuous monitoring of drug 
effects, side effects, contraindications and outright harmful effects which could result in a high 
degree of morbidity, and in some cases, even mortality, are essential to maximize benefits and 
minimize risks. No degree of care and caution at the pre-clinical and clinical testing stages can 
guarantee absolute safety, when a drug is marketed and prescribed to large populations across the 
country and outside. Because clinical trials involve several thousands of patients at most, less 
common side effects and ADRs are often unknown at the time a drug enters the market. Post 
marketing PV uses tools such as data mining and investigation of case reports to identify the 
relationships between drugs and ADRs. The drug regulatory agencies have the responsibility of 
having a well-established PV system to monitor ADRs during the drug development phase and 
later during the life time of a marketed drug [5]. A complex and vital relationship exists between 
wide ranges of partners in the practice of drug safety monitoring such as government, industry, 
health care centers, hospitals, academia, medical and pharmaceutical associations, poisons 
information centers, health professionals, patients, consumers and media [6-8]. Sustained 
collaboration and commitment are vital if future challenges in PV are to be met in order to 
develop and flourish. 
Since very few new drugs were discovered in India and hardly any new drug was launched for 
the first time in India in the past, there was no major compulsion to have a strong PV system to 
detect ADRs of marketed products. The experience from the markets where the drug was in use 
for several years before its introduction in India, was used by the companies and the regulatory 
agencies to assess the safety parameters and take corrective actions, such as the withdrawal or 
banning of the drug in question. The evolution of a new patent regime in the Indian 
pharmaceutical and biotechnology industries as a Trade Related Intellectual Property Rights and 
Services (TRIPS) makes it incumbent upon India to no longer copy patented products and market 
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them without license from the innovator company. The leading Indian companies, realizing the 
compulsions of the new regime, have already initiated investments of substantial resources for 
the discovery and development of new drugs needed for both Indian and International markets. 
This in turn means that during the coming year, research and development by the Indian 
pharmaceutical and biotech companies will hopefully lead to new drugs based on pre-clinical 
and clinical data generated mostly in India. In such cases, the Indian regulatory agencies cannot 
count on the experience of other markets to assess the incidence and prevalence of importance of 
a properly designed PV system in India. With the Indian companies’ capacity to develop and 
market new drugs out of their own research efforts, it is important that adequate PV standards are 
introduced to monitor ADRs of products first launched in India. 
1.1 Scope of PV 
The discipline of PV has developed considerably since the 1972 WHO technical report, and it 
remains a dynamic clinical and scientific discipline. It has been essential to meet the challenges 
of the increasing range and potency of pharmaceutical and biological medicines including 
vaccines, which carry with them an inevitable and sometimes unpredictable potential for harm. 
The risk of harm, however, is less when medicines are used by an informed health profession and 
by patients who themselves understand and share responsibility for their drugs. When adverse 
effects and toxicity appear, particularly when previously unknown in association with the 
medicine, it is essential that they are analyzed and communicated effectively to an audience that 
has the knowledge to interpret the information. This is the role of PV, of which much has already 
been achieved. But more is required for the integration of the discipline into clinical practice and 
public policy. To fulfill the PV obligations for its marketed products as per regulations, a 
pharmaceutical company in India has to essentially carry out activities such as collection, and 
expedited reporting of serious unexpected ADRs [9]. A typical setup for PV studies, including 
people involved on various levels, organizational units and their functions are shown in Figure 1. 
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Figure 1. A typical pharmacovigilance setup 
1.2 Vaccines and biological medicines 
Vaccines and biological medicines require modified systems of safety monitoring. They are 
often administered to healthy children. This applies particularly to vaccines used within a 
national immunization program. In many countries, those exposed to a particular vaccine 
represent the entire birth cohort and therefore a sizeable part of the entire population. People’s 
expectations of safety are high, and they are reluctant to countenance even a small risk of 
adverse events. Concerns regarding vaccine safety, real or imagined, may result in loss of 
confidence in the entire vaccine programs. This can result in poor compliance and a consequent 
resurgence in morbidity and mortality of vaccine-preventable disease. The difficulties in 
monitoring and dealing with vaccine safety are complicated by the problems inherent in 
determining the causal link between an adverse event following immunization and a vaccine 
[10,11]. For example, information on dechallenge and rechallenge is often missing, and vaccines 
are given to most of the country’s birth cohort at an age when coincidental disease is likely. 
Several vaccines are likely to be administered concurrently. The possibility of programmatic 
errors should never be overlooked. A programmatic error is a medical incident that is caused by 
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errors in the transportation, storage, handling or administration of vaccines. However, the 
responsibility of the regulatory authority is by no means limited to the safety of vaccines used in 
immunization programs. 
Several biological products are used in specific patient populations as preventive or curative 
measures. The efficient regulation of these products is crucial in order to avoid potential harm to 
the public as a result of substandard manufacture or improper transportation and storage of 
imported vaccines and biological medicines. In recent years, the safety of biological products 
and blood products has come under public scrutiny. Concerns about the safety of medicinal 
products of animal origin have been raised in connection with variant Creutzfeldt-Jacob disease 
(vCJD) and with contamination of blood and blood products by infectious organisms such as 
HIV and hepatitis B [12]. The quality of screening and sterilization procedures and appropriate 
selection of donors are linked to the risks of contamination. Such safety issues related to the use 
of plasma-derived medicinal products should fall under the aegis of PV programs. For that to 
happen, PV centers would have to consider the special issues related to safety of these products. 
Expertise in biological products, virology and medical microbiology would be required. Clinical 
trials in large patient populations are being considered for testing the efficacy and safety of 
biological medicine. 
2. Clinical Trials in India 
Global pharmaceutical companies have found India to be a preferred destination for clinical trials 
because India's clinical research space and opportunities are very attractive [13]. Some of the 
advantages for clinical trials that India has as are as follows: 
• High degree of compliance to international guidelines such as the International 
Conference on Harmonisation (ICH) / WHO Good Clinical Practice (ICH-GCP) 
and the regulations lay down by the US Food and Drug Administration. 
• Availability of well qualified, English speaking research professionals including 
physicians. 
• Ongoing support and cooperation from the government. 
• Lower cost compared to the west [14]. 
• Increasing prevalence of illnesses common to both developed and developing 
countries. 
• Availability of good infrastructure. 
• Changes in Patent Laws since January 2005. 
As per a recent report from Federation of Indian Chambers of Commerce and Industry (FICCI), 
scientific feasibility, medical infrastructure, clinical trial experience, regulations, 
commercialization potential and cost competitiveness are some of the growth drivers responsible 
for the metamorphosis of Indian clinical research in the recent past [15]. Indian-born contract 
research organizations (CROs) were able to offer the advantages of understanding the Indian 
scenario better, provide services at more competitive costs, and having better knowledge of 
Investigator sites in the country compared to the newer entrants in the market. India’s existing 
favorable regulatory framework and regulations with international standards, increasing 
awareness of good clinical practice guidelines and its implementation by clinicians are some of 
5 
Online Journal of Public Health Informatics * ISSN 1947-2579 * http://ojphi.org * 7(2):e223, 2015 
Role of Pharmacovigilance in India: An Overview 
 
OJPHI 
the main reasons propelling the growth of clinical research in India [16,17]. The therapeutic area 
wise distribution of clinical trials and availability of diverse patient population across major 
therapeutic segments in India is shown in Figure 2 [18]. 
 
Figure 2. Therapeutic area wise distribution of clinical trials outsourced to India. 
2.1. SWOT Analysis of Indian Clinical Trial Sector 
Strengths 
• Large population of over 1.2 billion, about 16% of the world’s population. 
• Huge pharmaceutical and biotech industry base with availability of skilled 
persons. 
• Third largest players in the world with 500 different active pharmaceutical 
ingredients [19]. 
• Currently accounts for 8% of global pharmaceutical production, being fourth in 
the world [20]. 
• Conducive initiatives to harness India’s innovative capability by government. 
• Huge data mining related to safety profile of drugs due to large population [21]. 
Weaknesses 
• As per 2009-10 estimates, expenditure on health sector was 2.1% of the total 
budget and 0.35% of the Gross domestic product (GDP) of India [22]. 
• Developed countries like United States, France, Switzerland and Germany, spent 
around 16%, 11%, 10.8% and 10.4% of their GDP respectively. 
6 
Online Journal of Public Health Informatics * ISSN 1947-2579 * http://ojphi.org * 7(2):e223, 2015 
Role of Pharmacovigilance in India: An Overview 
 
OJPHI 
• Less funding available for implementation of programs and issues of national 
importance such as PV [23]. 
Opportunities 
• The Indian population is the largest source of human biodiversity. 
• Consists of 4635 culturally and anthropologically well-defined populations, 
representing a perfect model to study efficacy, disease susceptibility, etiology, 
molecular pathology, and safety profile of drugs with respect to genetic 
diversity. 
• Excellent potential for skilled human resources required for an effective PV 
system due to >300 medical, >230 dental, >830 pharmacy and >650 
recognized nursing colleges in India [24]. 
Threats 
• Under reporting of ADRs. 
• Low availability of funds. 
• Less ADRs monitoring centers. 
2.2. Agencies Involved for Clinical Research Regulation In India 
Various regulatory agencies of India and their prominent roles in overseeing clinical trial along 
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Table 1. Roles of various regulatory agencies 
 
3. Role of pharmacogenomics in PV 
Pharmacogenomics (PGx) combines traditional pharmaceutical sciences such as biochemistry 
with annotated knowledge of genes, proteins, and single nucleotide polymorphisms (SNP). It is 
the technology that deals with the influence of genetic variation on drug response in patients by 
correlating gene expression or single-nucleotide polymorphisms (SNP) with a drug's efficacy or 
toxicity. By doing so, (PGx) aims to develop rational means to optimize drug therapy, with 
respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects [26]. 
Such approaches promise the advent of "personalized medicine"; in which drugs and drug 
combinations are optimized for each individual's unique genetic makeup. The science of 
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pharmacogenetics (PG) originated from the analysis of a few rare and sometimes serendipitously 
found extreme reactions (phenotypes) observed in some humans. These phenotypes were either 
inherited diseases or abnormal reactions to drugs or other environmental factors [27]. PG and 
PGx research remain iterative processes and there is more room for opportunities for 
improvement in each of the approaches. Figure 3 shows that multiple approaches have to be 
combined to obtain PGx knowledge that is of value for the development of new therapeutics or 
for the improvement of existing therapies. 
 
Figure 3. The pathways of pharmacogenomic research in clinical 
3.1. Find the gene for disease risk 
PG primarily deals with the therapeutic effects and the adverse effects of humans to drugs, 
poisons and other types of chemicals and environmental factors. However, soon after the field of 
PG emerged, this scope was broadened and the genetic polymorphisms were extensively studied, 
not only in relation to known specified exposures but also as susceptibility factors for diseases in 
general. In many of these studies the disease initiating conditions were not known. In parallel, 
the functional nature of the genes considered in PG research broadened from drug-metabolizing 
enzymes to almost all other classes, such as drug transport, DNA-repair, cell-cycle regulation 
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and signal transduction [28]. The overall number of publications studying PG polymorphisms in 
relation to disease risk exceeds, several-fold, those studying the polymorphisms in relation to 
response to drugs, and it is not possible to give a meaningful summary of that research on the 
hundreds of candidate genes as disease susceptibility factors. All recent genome-wide screens 
did not focus on the response to drugs but on the identification of genotypes predisposing to 
certain multi factorial and polygenic diseases. Some of the basic techniques of the wet and dry 
laboratories methods of PG and genomics are shown in Table 2. 
Table 2. Techniques for genotype analysis in pharmacogenetics and genomics 
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3.2 Statistics, bioinformatics and systems biology 
Previously reported by Brockmöller and Tzvetkov, it is mentioned that there are almost 12 
million SNPs in the human genome [exactly 11,811,594 SNPs, of which 5,689,286 are validated 
SNPs, according to the last release of the database dbSNP, build 127 (accessed March 2007): 
http://www.ncbi. nlm.nih.gov/SNP/Notes/build127_announce.txt]. In the near future, a clinical 
scientist will have to deal not only with clinical and laboratory data on his/her volunteers or 
patients but also with data on the patient’s 500,000 or 1 million SNPs. SNPs are DNA sequence 
variations that occur when a single nucleotide (A, T, C, or G) in the genome sequence is altered. 
SNPs occur every 100 to 300 bases along the 3-billion-base human genome, therefore millions of 
SNPs must be identified and analyzed to determine their involvement (if any) in drug response. 
Further complicating the process is our limited knowledge of which genes are involved with each 
drug response. Since many genes are likely to influence responses, obtaining the big picture on 
the impact of gene variations is highly time-consuming and complicated. Knowing one's genetic 
code will allow a person to make adequate lifestyle and environmental changes at an early age so 
as to avoid or lessen the severity of a genetic disease. Likewise, advance knowledge of particular 
disease susceptibility will allow careful monitoring, and treatments can be introduced at the most 
appropriate stage to maximize their therapy. 
Table 3. Bioinformatics databases and software tools for pharmacogenetics and genomics 
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The cytochrome P450 (CYP) family of liver enzymes is responsible for breaking down more 
than 30 different classes of drugs. DNA variations in genes that code for these enzymes can 
influence their ability to metabolize certain drugs. Less active or inactive forms of CYP enzymes 
that are unable to break down and efficiently eliminate drugs from the body can cause drug 
overdose in patients. Today, clinical trials researchers use genetic tests for variations in 
cytochrome P450 genes to screen and monitor patients. In addition, many pharmaceutical 
companies screen their chemical compounds to see how well they are broken down by variant 
forms of CYP enzymes [29]. Thus, the development of bioinformatics and genetic statistics plays 
a crucial role in the further development of PG and genomics (Table 3). Since the first 
interspecies comparisons of haemoglobin, protein sequences homology search has been an 
important tool to identify those segments in the genome that are particularly crucial for the 
biological function of a certain protein. Linkage of genetic variants on the same chromosome is a 
central basis of methods in genetic statistics. If a person has a certain variant at a certain position, 
the same person will probably also have other linked variants 10,000 or 50,000 bp nearby, and 
the same constellation will be found in several relatives of this person. Hence, PG and PGx are 
the most important reasons behind interethnic differences in drug effects which are studied in 
worldwide marketing of drugs and in PV shown in the Table 4. 
It is immediately evident that disease risk and response to drugs may depend on the 
combinations of several genes, and years ago scientists and companies emerged with the concept 
to sell predictive marker combinations. However, it is all too easy to identify in each study 
predictive marker combinations which are more predictive than the single markers alone. The 
aim, however, is to identify predictive marker combinations which remain predictive beyond the 
study in which they were identified. Predictive marker combinations may be identified as 
interaction terms in cross-tabulations, analyses of variance or logistic regression analyses, and 
data mining tools, such as recursive partitioning, are particularly helpful for this. The situations 
in which such recursive partitioning should be performed in whole genome scans is not yet clear: 
in the entire data sets or, as some authors have performed, in subsets identified in a 
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Table 4. Summarizing the Role of PGx in PV 
 
 
4. Data Mining for PV 
PV, also known as drug safety surveillance, is the science of enhancing patient care and patient 
safety regarding the use of medicines by collecting, monitoring, assessing, and evaluating 
information from healthcare providers and patients. In that view, PV can be divided into two 
stages such as premarketing surveillance – information regarding ADRs is collected from pre-
clinical screening and phases I to III clinical trials; and post-marketing surveillance – data 
accumulated in the post approval stage and throughout a drug’s market life shown in Figure 4 
[31]. 
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Figure 4. Pharmacovigilance at different stages of drug development 
PV has relied on biological experiments or manual review of case reports; however, due to the 
vast quantities and complexity of data to be analyzed, computational methods that can accurately 
detect ADRs in a timely fashion have become a critical component in PV. Large-scale compound 
databases containing structure, bioassay, and genomic information, as well as comprehensive 
clinical data sets such as electronic medical record (EMR) databases, have become the enabling 
resources for computerized ADR detection methods [32]. 
4.1 Premarketing surveillance 
PV at the pre-marketing stage has been devoted to predict or assess potential ADRs early in the 
drug development pipeline. One of the fundamental methods is the application of preclinical in 
vitro Safety Pharmacology Profiling (SPP) by testing compounds with biochemical and cellular 
assays. The hypothesis is that if a compound binds to a certain target, then its effect may 
translate into possible occurrence of an ADR in humans. However, experimental detection of 
ADRs remains challenging in terms of cost and efficiency. There have been numerous research 
activities devoted to developing computational approaches to predict potential ADRs using 
preclinical characteristics of the compounds or screening data. Most of the existing research can 
be categorized into protein target-based and chemical structure-based approaches. Others have 
also explored integrative approach [33]. 
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4.2 Post-marketing surveillance 
Although a drug undergoes extensive screening before its approval by the Food and Drug 
Administration (FDA), many ADRs may still be missed because the clinical trials are often 
small, short, and biased by excluding patients with comorbid diseases. Premarketing trials do not 
mirror actual clinical use situations for diverse (e.g. inpatient) populations, thus it is important to 
continue the surveillance postmarket. PV plays an essential role in the post-market analysis of 
newly developed drugs [34,35]. Pharmaceutical companies' competition along with rigorous 
regulatory evaluation procedures empowers a complex research and development process before 
launching a new drug into the market. Several unique data sources are available for 
postmarketing PV [36]. 
PV research is based on the analysis of "signals". The World Health Organization (WHO) 
defines signals as undisclosed assertions on direct relationships between effects on the human 
organism and a drug to induce adverse events [37]. To generate comprehensive signal datasets, 
clinicians and researchers use spontaneous reporting systems (SRS). Electronic SRSs are already 
in place throughout some European countries and the United States. Likewise, other solutions, 
such as general practitioners’ databases analysis, post market studies or prescription monitoring, 
among others, are being thoroughly explored. Nevertheless, the majority of data is not publicly 
available for researchers, which, jointly with other barriers, severely limits signal detection [38-
40]. Although drug companies are required to track and manage adverse events reported by 
clinicians, lawyers or patients, the detection process relies mostly on the physician's ability to 
recognize a given trait as a drug adverse event. Whereas the problem for collecting and filtering 
ADR data from multiple distributed nodes has already been studied in the past, researchers 
continue to pursue the best strategies to delve into the wealth of collected data in conjunction 
with other post drug administration inputs [41]. With data and text-mining techniques 
scavenging millions of electronic medical records, PV researchers are now faced with the 
problem of delivering knowledge-oriented tools and services that exploit the scope of collected 
data. Ultimately, the adequate exploration of these data will pave the way for improved drug 
evaluations, critical for pharmaceutical companies, regulatory entities and researchers [42]. 
4.3 Spontaneous Reports 
A spontaneous report is an unsolicited communication by health care professionals or consumers 
to a company, regulatory authority, or other organization that describes one or more ADRs in a 
patient who was given one or more medicinal products and that does not derive from a study or 
any organized data collection scheme. Spontaneous reports play a major role in the identification 
of safety signals once a drug is marketed. In many instances, a company can be alerted to rare 
adverse events that were not detected in earlier clinical trials or other pre-marketing studies 
[43,44]. 
Spontaneous reporting of ADRs and adverse events is an important tool for gathering the safety 
information for early detection. Case reports collected by such a system represent the source of 
information providing the lowest level of evidence and highest level of uncertainty regarding 
causality. Spontaneous reporting has advantages in that it is available immediately after a new 
product is marketed, continues indefinitely and covers all patients receiving the drug. It is the 
most likely method of detecting new, rare ADRs and frequently generates safety signals which 
need to be examined further [45]. The main limitations are the difficulty in recognizing 
previously unknown reactions, particularly events that are not usually thought of as being ADRs, 
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and under-reporting, which is variable and sensitive to reporting stimuli and difficult to quantify. 
It usually does not confirm hypotheses; although situations exist where spontaneous reporting 
data alone allow conclusions that a signal indeed represents a true ADR [46]. 
4.4. Yellow Card Scheme 
Yellow card schemes (YCS) were applied to spontaneous reporting systems. It was established in 
1964 as a result of the thalidomide tragedy. Since then, the system has become one of the major 
international PV resources [47]. The yellow cards are classified into seven priorities by a 
member of the scientific staff according to the drugs and the nature of the ADR shown in Figure 
5. 
 
Figure 5. Adverse drug reactions online information tracking and yellow card system Sources of 
data 
The YCS is run jointly by the Medicines Control Agency (MCA) which is the regulatory agency 
and the Committee on Safety of Medicines (CSM) which is the experts committee. Since 1991, 
the YCS has been enhanced by a new computer system, the ADROIT (Adverse Drug Reaction 
Online Information Tracking) system. ADROIT is different from other databases. Not only does 
it store the details of the report, but also the image of the yellow card in the optical system. 
Multiple users can view any yellow card on screen at the same time. The reports are prioritized 
so that serious adverse drug reactions receive early attention [48]. 
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Figure 6. Adverse Drug Reaction reporting form 
4.5 Detection and reporting 
A healthcare professional or marketing authorization holder reports suspected ADRs related to 
one or more medicinal products, to a PV centre. Reports are made on writing report forms, by 
telephone, electronically, or by any other approved way [49]. Reports are collected and validated 
by the PV centre and are usually entered into a database. Serious reactions should be handled 
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with the highest priority. The database is used to identify potential signals and analyze data in 
order to clarify risk factors, apparent changes in reporting profiles etc [50]. A typical ADR 
reporting form is shown Figure 6. 
Systematic methods for the detection of safety signals from spontaneous reports have been used. 
These methods include the calculation of the proportional reporting ratio, as well as the use of 
Bayesian and other techniques for signal detection. Data mining techniques have also been used 
to examine drug-drug interactions [51]. Data mining techniques should always be used in 
conjunction with, and not in place of, analyses of single case reports. Data mining techniques 
facilitate the evaluation of spontaneous reports by using statistical methods to detect potential 
signals for further evaluation (Figure 7). 
 
Figure 7. Pharmacovigilance systematic methods for the Evaluation of Spontaneous Reports 
collected from different data sources. 
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This tool does not quantify the magnitude of risk, and caution should be exercised when 
comparing drugs [52]. Furthermore, when using data mining techniques, consideration should be 
given to the threshold established for detecting signals, since this will have implications for the 
sensitivity and specificity of the method (a high threshold is associated with high specificity and 
low sensitivity). Confounding factors that influence spontaneous adverse event reporting are not 
removed by data mining. Results of data mining should be interpreted with the knowledge of the 
weaknesses of the spontaneous reporting system and, more specifically, the large differences in 
the ADR reporting rate among different drugs and the many potential biases inherent in 
spontaneous reporting. All signals should be evaluated recognizing the possibility of false 
positives. In addition, the absence of a signal does not mean that a problem does not exist. 
5. PV in India 
In India, consideration for the surveillance of ADRs developed relatively late, as traditionally 
there was no concept of surveillance of medicines in the country. Even though PV is still in its 
infancy, it is not new to India. It was not until 1986 when a few physicians, mainly from 
academic institutions, called for greater attention to be devoted to the potential adverse effects of 
prescription medicines and rational prescribing of medicines. This led to the formation of the 
first ADR monitoring program consisting of 12 regional centers, each covering a population of 
50 million, but was unsuccessful [53]. Nothing much happened until a decade later when India 
joined the WHO Adverse Drug Reaction Monitoring Programme based in Uppsala, Sweden in 
1997. Three centers for ADR monitoring were identified, mainly based in the teaching hospitals: 
A National Pharmacovigilance Center located in the Department of Pharmacology, All India 
Institute of Medical Sciences (AIIMS), New Delhi and two WHO special centers in Mumbai 
(KEM Hospital) and Aligarh (JLN Hospital, Aligarh). These centers were to report ADRs to the 
drug regulatory authority of India. The major role of these centers was to monitor ADRs to 
medicines marketed in India. However, they were non-functional as information about the need 
to report ADRs and about the functions of these monitoring centers never reached the prescribers 
and there was lack of funding from the government. This attempt was unsuccessful, and hence, 
again from 1 January 2005, the WHO-sponsored and World Bank-funded National 
Pharmacovigilance Program (NPVP) for India was formulated [54]. NPVP structure is shown in 
Figure 8. 
The NPVP, established in January 2005, was to be overseen by the National Pharmacovigilance 
Advisory Committee based at the Central Drugs Standard Control Organization (CDSCO). Two 
zonal centers, the South-West (SW) zonal center (located in the Department of Clinical 
Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai) and the North-East (NE) 
zonal center (located in the Department of Pharmacology, AIIMS, New Delhi) were to collect 
the information from all over the country and send it to the committee as well as to the Uppsala 
Monitoring Centre (UMC) in Sweden [55]. Three regional centers would report to the Mumbai 
center and two to the New Delhi one. Each regional center, in turn, would have several 
peripheral centers (24 in total) reporting to it. The program had three broad objectives. The short-
term objective was to foster a reporting culture, the intermediate objective was to involve large 
number of healthcare professionals in the system in information dissemination, and the long-term 
objective was for the program to be a benchmark for global drug monitoring. However, this 
program also failed [56]. 
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Figure 8. National Pharmacovigilance Program zone structure 
5.1 Current PV program in India 
Recognizing the need to restart the NPVP, in a brainstorming workshop jointly organized by the 
Department of Pharmacology, AIIMS and CDSCO in late 2009, the framework of the new and 
current program was formulated. The program, now rechristened as the Pharmacovigilance 
Programme of India (PVPI) was initiated by the Government of India on 14th July 2010 with the 
AIIMS, New Delhi as the National Coordination Centre (NCC) for monitoring ADRs in the 
country for safe-guarding public health. In the year 2010, 22 ADR monitoring centers including 
AIIMS, New Delhi was set up under this programme [57]. To ensure implementation of this 
programme in a more effective way, the NCC was shifted from the AIIMS, New Delhi to the 
Indian Pharmacopoeia Commission (IPC), Ghaziabad, Uttar Pradesh on 15th April 2011 [58]. 
The main aim of the NCC at IPC is to generate an independent data on the safety of medicines, 
which will be at par with global drug safety monitoring standards. Year-wise target phases of 
PVPI is shown in Figure 9. 
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Figure 9. Targets for the Pharmacovigilance Program in India 
The recent report of the AMC’s under the PVPI has been reported based on the entry of ADR’s 
in the VigiFlow. In total, NCC received 3,537 Individual Case Safety Reports (ICSRs) and 1,948 
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Adverse Events Following Immunization (AEFI) from the AMCs in the month of May 2014. 
Seven more centres have been given access to VigiFlow by UMC, Sweden. Out of 97 AMC’s 
where the Vigiflow is functional, 82 centres have provided the ADR’s reports via VigiFlow. It 
was observed that PGIMER, Chandigarh entered the highest number of ADR’s reports (311 
reports in May 2014) followed by 225 reports from MMC, Chennai; 216 reports from JSS, 
Mysore; 184 reports from UCMS-GTBH, Delhi; 167 reports from LHMC, New Delhi. These 
reports are under (quality and medical) assessment at NCC [59]. Current status of NCC-PVPI 
published on May 31, 2014 by IPC that is shown in Table 5. 
Table 5. Current Status of NCC-PVPI 
 
5.2 Framework of the new program 
The center at IPC focuses on developing India’s own database on drug information and ADRs, 
so that India will not have to be dependent on data from other countries to take decisions relating 
to the banning and suspension of drugs. At present, India does not have a strong database on 
ADRs and has to depend on information from Western countries. So far, only 2823 ADRs have 
been reported since September 2010 under the current PVPI, which is very small to draw any 
meaningful conclusion implicated for any particular signal [60]. 
Table 6. Chronological developments in PV sector with special reference to India 
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It is being envisaged that all the medical institutions, hospitals, colleges, and public health 
programs in the country, both government as well as private, will take part in the PVPI and 
report ADRs to IPC, so that all the data generated will be collated and analyzed at one place. The 
chronological developments in the field of PV with special reference to India are given in Table 
6 [61]. PVPI administered governing body and monitored centers are shown in Figure 10. 
 
Figure 10. Pharmacovigilance program in India and responsibilities. 
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The program was envisaged to be rolled out in three phases. Phase I would include 40 ADR 
monitoring centers (AMC) to be rolled out in 2010. The program would be expanded in phase II 
to include up to 140 MCI recognized medical colleges by 2011. Until the end of 2011, a total of 
only 60 AMCs have been included. Phase III would ultimately cover the entire healthcare system 
by 2013 [62]. The AMCs get operational and logistic support from the respective zonal CDSCO 
centers situated at Ghaziabad, Kolkata, Mumbai, and Chennai. The zonal CDSCO centers will be 
under administrative control of the CDSCO headquarters at New Delhi. Organizational structure 
of PVPI and respective responsibilities of are shown in Figure 11 [63]. 
 
Figure 11. Governance structure 
5.3 ADR data flow 
ADR reports were collected at the AMC by the PV staff who checked for validity of the report 
and conducted provisional causality assessment. The ADR forms are then dispatched to the 
coordinating center. The AMC staff maintains a log of all the activities of the center and the 
selected AMCs also carry out focused ADR monitoring of drugs as per the watch list. The 
coordinating centers are conducting causality assessment and upload the reports into the PV 
database. The coordinating center also prepare a consolidated report of ADRs collected at 
defined time intervals and then implement and integrate PV activities into public health 
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programs involving mass usage of drugs [64]. Finally, the integrated ADR data is then 
transmitted through VigiFlow interface into the UMC adverse reaction database where signal 
processing can be carried out [65] (Lindquist 2008). Programme communication of ADR data 
flow is shown in the Figure 12. There is a quality review panel which ensures the quality of ADR 
data that has been constituted for maintaining quality assurance in the program. All the centers 
will be assessed based on performance metrics criteria, completeness of reports, training 
imparted, and other parameters mentioned in the PV program protocol. 
 
Figure 12. ADR data Program Communications 
5.4 Haemovigilance Programme 
Haemovigilance is a continuous process of data collection and analysis of transfusion-related 
adverse reactions in order to investigate their causes and outcomes and prevent their occurrence 
or recurrence. IPC, in collaboration with the National Institute of Biologicals (NIB) at Noida, has 
launched a Haemovigilance Programme of India (HVPI) across the country under its PVPI with 
two main objectives. First to track adverse reactions/events and incidence associated with blood 
transfusion and blood product administration, and second to help identify trends, recommend 
best practices and interventions required to improve patient care and safety, while reducing 
overall cost of the healthcare system [66]. 
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The recognition and management of transfusion reactions (TRs) are critical to ensure patient 
safety during and after a blood transfusion. Transfusion reactions are classified into acute 
transfusion reactions (ATRs) or delayed transfusion reactions, and each category includes 
different subtypes. Different ATRs share common signs and symptoms which can make 
categorization difficult at the beginning of the reaction. Moreover, TRs are often under-
recognized and under-reported. To ensure uniform practice and safety, it is necessary to 
implement a national haemovigilance system and a set of national guidelines establishing 
policies for blood transfusion and for the detection and management of TRs [67]. In this context 
the haemovigilance programme was launched on 10th Dec 2012 and has already enrolled 90 
Medical Colleges of India under PVPI as an integral part of PVPI. NIB is the coordinating centre 
for HVPI to collect and collate data pertaining to Haemovigilance coming from medical 
institutions all over the country. A software “Haemo-Vigil” has been developed by IT Division 
of the NIB [68]. 
5.5 Visibility, communication, and feedback of PVPI 
A website created by CDSCO is dedicated to PVPI. In phase II of the program, there is a 
provision for online reporting of ADRs by healthcare professionals who are not covered under 
the program. The CDSCO headquarters, in collaboration with NCC, published a quarterly 
“Medicine Safety Newsletter” comprising 4-16 pages. Approximately 3000 copies will be 
printed for circulation to healthcare institutions across the nation. A Medicine Safety Card has 
been included in the Medicine Safety Newsletter, and in national medical journals, to ensure that 
healthcare professionals not covered under the program can report ADRs directly to any of the 
centers. These are creating awareness about the program and ensure reporters get adequate 
feedback and remain motivated. In addition, to enhance the awareness and visibility of the 
programme, focused workshops, symposia, and group meetings on ADR reporting and causality 
assessment are carried out at regular intervals by all the centers [69]. 
5.6 Guideline of PVPI 
Globally, many countries have formulated their own PV guidelines with the aim of having a 
systematic process of safety reporting. The ICH has six guidelines pertaining to various aspects 
of drug safety [70,71]. E2A- Clinical Safety Data Management: Definitions and standards for 
expedited reporting, E2B- Clinical Safety Data Management: Data elements for transmission of 
individual case safety reports, E2C- Clinical Safety Data Management: Periodic safety update 
reports for marketed drugs, E2D- Post-approval Safety Data Management: Definitions and 
standards for expedited reporting, E2E-Pharmacovigilanve planning, and E2F- Development 
Safety Update Report. Hence, legislative requirements of PV in India are guided by 
specifications of Schedule Y of the Drugs and Cosmetics Act 1945. Schedule Y also deals with 
regulations relating to pre-clinical and clinical studies for development of a new drug, as well as 
clinical trial requirements for import, manufacture, and obtaining marketing approval for a new 
drug in India. Schedule Y was revised and amended on 20 January 2005 as a continued 
commitment of the drugs controller general of India (DCGI) to ensure adequate compliance of 
PV obligations of pharmaceutical companies. An attempt has been made in the amended 
Schedule Y to better define the roles and responsibilities of pharmaceutical companies for their 
products, as well as relating to reporting of AEs from clinical trials [72]. 
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India has only a small section of Schedule Y dedicated to drug safety, which when viewed in 
light of contemporary global practice, seems to have many lacunae. There is thus a felt need that 
CDSCO must formulate detailed PV guidelines. Such guidelines shall incorporate all relevant 
areas of pre and post marketing safety, address the current lacunae and bring about clarity on 
issues as discussed above. Most importantly, the guidelines shall be in tune with the current 
international norms, so as to support India’s growth like any participant in multinational clinical 
trials [73]. 
5.7 The challenges of PV in India 
The biggest challenge facing the PVPI is the gross underreporting of adverse effects. There are 
many reasons for this, including lack of medical expertise in drug administration and adequate 
skilled resources in PV, and inadequate nationwide awareness of PV. The other challenges are 
infrastructure which are still conservative, wide time interval between guidelines and laws, 
orthodox attitude to new drug research, and PV and regulatory inspections that are almost non-
existent. The system needs to be refined with the help of PV experts in collaboration with 
information technology (IT) because India boasts of a highly developed IT sector. Since PV 
deals with large numbers of ADRs, it would be wise for PV experts to collaborate with software 
professionals to develop and build a robust system. Software programs developed can be used 
for collection and analyses of data sets, determining trends of drug usage in various disease 
areas, compliance, medication errors and drug interactions leading to ADRs. Moreover, with 
more clinical research and PV outsourcing work now being conducted in India, it has been 
worthwhile for the DCGI to invest in a robust PV system to enable assessors and decision 
makers to analyze safety data and take regulatory decisions without the need to depend on other 
countries [74]. 
However, sometimes ADRs are not recognized by the physicians on admission and ADRs may 
be responsible for the death of many patients. Furthermore, the financial cost of ADRs to the 
healthcare system is also vast [75]. In the market, when new medicines are launched without 
long term safety studies by the regulatory authorities, patients self-medicate and switch from 
prescription-only medicines (POM) to over-the-counter (OTC) more widely, and this is the main 
reason of exposing itself to ADRs. In the earlier period, India's regulatory agencies and drug 
companies based their safety assessments on experiences derived from long-term use [76]. In 
recent years, many Indian companies are increasing their investment in research and 
development and are enhancing their capacity to develop and market new drugs with their own 
research efforts. Once a product is marketed, new information will be generated, which may 
have an impact on the benefit-risk profile of the product. The detailed evaluation of the new 
information generated through PV activities is important for all products to ensure their safe use. 
Hence, DCGI should take some tough decisions and make commitments to make PV mandatory 
and start the culture of PV inspections. 
5.8 Future prospects 
As future prospects increase, PV systems capable to detect new ADRs, and taking regulatory 
actions are needed to protect public health. Little emphasis has been put into generating 
information that can assist a healthcare professional or a patient in the decision-making process. 
The gathering and communication of this information is an important goal of PV [77]. 
Information about the safety of drug active surveillance is necessary. When develop new 
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methods for active post-marketing surveillance, one has to keep in mind that the important to 
collect complete and accurate data on every serious reported event. Spontaneous reporting is a 
useful tool in generating signals, but the relatively low number of reports received for a specific 
association makes it less useful in identifying patient characteristics and risk factors [78]. PV 
methods must also be able to describe which patients are at risk of developing an ADR. As a 
source of information, the PV approach would be consistent with the growing patient 
involvement in drug safety. The PG could  play  a  role  in  identifying  individual  risk  factors  
for  the occurrence of certain ADRs. In the future, PV has to concentrate on the patients as a 
source of information in addition to the more traditional groups, such as the health professionals. 
At present, the DCGI should act quickly to improve PV so as to integrate Good 
Pharmacovigilance Practice (GPP) into the processes and procedures to help ensure regulatory 
compliance and enhance clinical trial safety and post marketing surveillance. An appropriately 
working PV system is essential if medicines are to be used carefully. It will benefit healthcare 
professionals, regulatory authorities, pharmaceutical companies and the consumers. It helps 
pharmaceutical companies to monitor their medicines for risk [79]. Post-marketing PV is 
currently a challenging and laborious process, not only industry-wide, but also for regulatory 
agencies. 
The aim of the PV is to receive the information, documentation of the work and knowledge 
online while giving priority to the new and important safety issues. Non-serious events have less 
priority than serious events but important in comparing the changes in health, although they are 
also screened routinely [80]. In present time, GlaxoSmithKline has created a powerful new 
approach to PV, integrating traditional, case-based PV methods with disproportionality and data 
visualization tools. These tools exist within a system framework that facilitates in-stream review, 
tracking of safety issues and knowledge management [81]. This very innovative tool and the 
processes will help to advance PV by improving efficiency and providing new analytical 
capabilities. Similar approach may be adopted by pharmaceutical companies for prompt 
detection and analysis of ADRs. Transparency and communication would strengthen consumer 
reporting, which are positive steps towards involving consumers more in PV. 
6. Conclusion 
The PV in India has become an important public health issue as regulators, drug manufacturers, 
consumers, and healthcare professionals are faced with a number of challenges. The PV in India 
continues to grow, evolve, and improve. India is the largest producer of pharmaceuticals and 
now emerging as an important clinical trial hub in the world. Apparently, the requirements for 
professional specialization, a combined view on PGx and clinical requirements are needed. That 
helps to identify factors that increase the risk of unwanted outcomes from drug therapy and prior 
to commencing drug treatment and in tailoring drug treatment for individual patients. The PV 
has also involved in Data Mining Technology in spontaneous reports submit to the national 
surveillance systems. The PVPI is coordinated at IPC through NCC under the control of Indian 
Government to generate an independent data on safety of medicines, which will be at par with 
global drug safety monitoring standards. National and regional PV systems are well-adapted 
bodies, attuned to the intricate collection and analysis of ADR data that leads to   timely   alerts   
and   interventions   to   protect   population   health. Furthermore, it is responsible in India of 
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entire campaign to improve PV knowledge and increase the number of ADRs reports up to the 
gold standard level established by the WHO.  
The adverse events reported by PV system will potentially benefit to the community due  to  
their  proximity  to both  the population and public health practitioners, in terms of language and 
knowledge of the lifestyle and habits of patients, enables easy contact with reporters, for example 
by telephone, Email, text massages by mobile phones. The development of new and effective 
medicinal products makes a positive contribution to the health and well being of individuals. 
However, there is a need to improve PV systems to more effectively monitor and take action on 
safety issues associated with medicines to enhance their contribution to public health. Hence, PV 
for medicinal product safety to help the patients get well and to manage optimally or ideally, 
avoid illness is a collective responsibility of industry, drug regulators and clinicians and other 
healthcare professionals. The financial support and future projects should help to achieve a more 
comprehensive PV activity in India. 
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